Clinical Trial Search

Primary: Change in Heart Failure Self-Care Behaviors (EHFScB-9 Total Score) — -17.89 EHFScB-9 total scores on a scale (9-45) — p=< 0.001

Primary: One-Year Overall Survival Rate — 16 Participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 1; 1; 0; 1 Participants

Primary: Leukoglycemic Index (LGI) — 1.081; 1.230 mg/dL*cells per mm^3

Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants

Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 57.38; 70.59; 7.85 percentage of participants — p=<0.0001

Primary: Groin Wound Complication — 6; 19; 1 Participants

Primary: Brain Activity Changes in Migraine Patients in Response to Treatment — -0.249; 0.679; 0.680; 1.06 Log ratio % signal change (Insula/Sp5)

Primary: MATRICS Consensus Cognitive Battery Global Composite T-score (MCCB-C) — 40.59 T-Score — p=0.078

Primary: HPV Vaccination (≥1 Dose), 11-14 Year Olds at 12 Months — 3189; 3833; 4260 Participants

Primary: Cancer-related Fatigue Severity Using The Brief Fatigue Inventory. — 0.56; 4.19; 4.93 Scores on a scale

Primary: Visual Clarity on Endoscope Screen During Shoulder Arthroscopy (Intraoperative) — 7.79; 7.24 units on a scale

Primary: Mean Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 — -58.2; 2.6 Percent Change — p=<0.001

Primary: Glycemic Control (HbA1c) — 8.8; 9.0 mean percentage of HbA1c

Primary: Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16 — 13.0; 69.1 percentage of…